Health Care

Related Outside Content

The BioShares Biotechnology Products Fund (NasdaqGM: BBP) has capitalized on a string of acquisitions and outperformed other biotechnology- and pharmaceuticals-related exchange traded funds. BBP, which follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, gained 4.0% over the past week and increased 9.1% over the past three […]

While the markets have been weighed down by various uncertainties, stock exchange traded funds may still strengthen as many still expect the S&P 500 to maintain its momentum, with the health care sector leading the charge. Industry analysts in aggregate predict the S&P 500 will experience a 10% advance in price over the next year, […]

Biotechnology-related exchange traded funds are stuck in a malaise, with the underlying biotech sector declining for the ninth consecutive session, its longest selloff in a twenty years. Since June 6, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, declined 10.3%. Related: Hit The Lab With These 17 Biotech ETFs The […]

Janus Capital Group expanded its offerings to include four new exchange traded funds that track various health and living-related themes. Janus rolled out The Health and Fitness ETF (NasdaqGM: FITS), The Long-Term Care ETF (NasdaqGM: OLD), The Organics ETF (NasdaqGM: ORG) and The Obesity ETF (NasdaqGM: SLIM). Each fund comes with a 0.50% expense ratio. […]

Revitalizing the merger and acquisition outlook for biotech sector exchange traded funds, Pfizer (NYSE: PFE) announced it will buy biopharma company Anacor Pharmaceuticals (NasdaqGS: ANAC). Pfizer paid a 55% premium to Anacor’s closing price last Friday for $5.2 billion, gaining control over an experimental eczema treatment crisaborole, which posted strong results in Phase 3 clinical […]

While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on increased merger and acquisition activity. About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories (NYSE: ABT) agreeing to acquire St Jude Medical […]

Each week ETF Trends publisher Tom Lydon sits down for “ETF of the Week” for MarketWatch on Chuck Jaffe’s MoneyLife Show where he highlights big movers and disappointments among exchange traded funds. This week, he looked at the Health Care Select Sector SPDR Fund (XLV). XLV recently moved above long-term resistance at its 200-day simple moving average. Click here to […]

Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, declined 17.0% […]

Expensive biologics have weighed on health care consumers. However, as the government tries to contain the soaring costs, a generic drugs-related exchange traded fund could capitalize on the growth of cheaper biosimilars. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which […]

The health care sector remains one of the worst performing areas of the market, despite the recovery off the Feb. 11 lows. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead. Based on […]

Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds that track the biotechnology sector surged as traders speculated that the two companies could court other merger targets. Biotechnology sector-related ETFs led gains on Wednesday. The BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), […]

The so-called earnings recession may have extended over the first quarter. Nevertheless, exchange traded fund investors may still find opportunities in some sectors that continue to grow. Capital IQ aggregate first quarter 2016 S&P 500 earnings-per-share are estimated to be $26.37, or a 7.5% decline year-over-year, compared to a 4.2% decrease for Q4 2015, Sam […]

Unloved ETF healthcare segment may provide a cheap opportunity for bargain hunters SPDR S&P 500 ETF (NYSEArca: SPY) is up 0.8% so far this year Investors may also be trying to catch a falling knife after the huge sell-off in the biotech sub-sector as biotechs remain in bear market territory Healthcare stocks, notably biotechnology names, […]

Slow and steady value and conservative sectors are leading market gains RPV was best performing non-leveraged ETF across various Morningstar style categories  Close behind was RZV, which like RPV, targets companies exhibiting a value characteristic Since the start of the bull market, we may come to expect growth stocks like biotechnology and technology-sector exchange traded […]

India is expanding its generic drug industry and supporting a sector-related exchange traded fund as the emerging market plays a greater role in the global health care sector. “Indian generic drugmakers have moved upwards on the global value chain and managed to gain a foothold in regulated markets such as the US and Europe,” according […]

The earnings season has been disappointing and weighed on investor confidence through one of the worst starts to a new year. Nevertheless, there are some areas that may pull through the malaise, with decent growth propping up the sector-related exchange traded funds. Aggregate fourth quarter 2015 S&P 500 earnings-per-share are expected to fall 4.94% year-over-year, […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

The $3.5 billion First Trust Dorsey Wright Focus 5 ETF (NasdaqGM: FV) has helped exchange traded fund investors target some high-flying sectors, but the momentum strategy recently cut its biotech position for a defensive play. The First Trust Dorsey Wright Focus 5 ETF follows DWA’s relative strength ranking system where sector ETFs are compared to […]

Health care investors can now target a growing segment of the pharmaceutical industry through a relatively new generics drug exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which tracks a number of global drug makers that generate significant […]

As volatility spikes and markets gyrate, some investors have turned to more conservative stocks and defensive sector exchange traded funds to ride out the storm. For instance, many have traditionally turned to defensive sectors like utilities, consumer staples and health care – sectors that would hold up in any economic cycle as U.S. consumers will […]

While the broad U.S. equities market strengthened Thursday, the biotechnology sector looked under the weather, with sector-related exchange traded funds slipping to 52-week lows. On Thursday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB) fell 3.6% and SPDR S&P Biotech ETF (NYSEArca: XBI) dropped 3.5%. Year-to-date, IBB declined 19.2% and XBI decreased 26.4%. Both biotech ETFs […]

As the equities market experienced its worst start to a new year, exchange traded fund investors fled growth sectors and jumped into defensive stocks, along with betting on a valuation play. Investors’ eyes are on the tech space this week amid a spate of fourth quarter earnings results, but the technology sector was among the […]

Biotechnology stocks and sector-related exchange traded funds rallied late Wednesday but could not maintain their momentum after a high profile drug trial failure. Alkermes (NasdaqGS: ALKS), a central nervous-system drug developer, revealed two late-stage Phase 3 studies of its treatment for depressive disorder did not meet primary endpoints, Reuters reports. KMI shares plunged 42.3% Thursday, […]

As the markets digest fourth quarter earnings results, U.S. markets are expected to fall further into an earnings recession, with S&P 500 companies likely to show decline in profits for the third consecutive quarter. Nevertheless, there some sectors and related exchange traded funds that may pull through. Profits are expected to decline by 7.2% in […]

Breakout new drugs usually receive all the attention in the pharmaceuticals space, but generic drugs make up the bulk of the industry. Now, investors can target the rising growth in the generics space with a new sector-specific exchange traded fund. Van Eck Global’s Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) began trading Wednesday, according to […]

As investors try to shift around positions capitalize on short-term earnings moves, exchange traded funds that track the healthcare, telecom and tech sectors may outperform while the energy sector is largely expected to bring up the rear. Goldman Sachs analysts argue that the energy sector will depress U.S. fourth-quarter earnings and pressure growth for the […]

We are heading into the earnings season, and investors are growing concerned over the outlook for biotechnology stocks and sector-related exchange traded funds as bellwether Celgene Corp. (NasdaqGS: CELG) expects weaker-than-expected growth last year. Biotech stocks were among the worst performers Monday, with the ALPS Medical Breakthroughs ETF (NYSEArca: SBIO), which focuses on small- and […]

Health care sector exchange traded funds are among the healthier segments of the U.S. equities market and could continue to grow stronger ahead. UBS equity strategists argue that investors should overweight the health care stocks due to the sector’s “earnings momentum, strong top-line growth, attractive dividend yield and potential for further share buybacks,” reports Luke […]

After a stellar October, the equities market and stock exchange traded funds had a more tepid November, with traders waiting for a potential rate hike in December. Over November, the Dow Jones Industrial Average was down 0.6%, the Nasdaq Composite was 0.4% lower and the S&P 500 dipped 1.1%. The best performing non-leveraged ETFs over […]

U.S. companies recently revealed their largest annual profit decline since the recession, suggesting that the economy and stock exchange traded funds are moving toward the late-cycle phase. Corporate America’s profits dropped to $2.1 trillion in the third quarter, or down 1.1% from the second quarter, and fell 4.7% year-over-year, the largest annual decline since the […]